HRs (95% CI) for development of isolated IFG or IGT according to the quartiles of %FVC*or FEV1%†
| I | II | III | IV | p for trend | |
|---|---|---|---|---|---|
| IFG | |||||
| %FVC | |||||
| Model 1 | 1.0 | 0.85 (0.38 to 1.92) | 0.81 (0.36 to 1.79 | 1.96 (0.71 to 5.26) | 0.31 |
| Model 2 | 1.0 | 1.07 (0.48 to 2.39) | 1.35 (0.60 to 3.03) | 0.54 (0.20 to 1.49) | 0.32 |
| FEV1/FVC | |||||
| Model 1 | 1.0 | 0.96 (0.42 to 2.17) | 1.20 (0.51 to 2.86) | 0.98 (0.43 to 2.27) | 0.95 |
| Model 2 | 1.0 | 0.99 (0.43 to 2.31) | 0.84 (0.35 to 2.00) | 1.04 (0.45 to 2.47) | 0.96 |
| IGT | |||||
| %FVC | |||||
| Model 1 | 1.0 | 1.96 (1.00 to 3.85) | 2.63 (1.27 to 5.56) | 3.03 (1.43 to 6.67) | 0.006 |
| Model 2 | 1.0 | 2.22 (1.02 to 3.88) | 2.26 (1.07 to 4.78) | 2.74 (1.26 to 5.98) | 0.02 |
| FEV1/FVC | |||||
| Model 1 | 1.0 | 2.13 (0.96 to 4.76) | 1.67 (0.81 to 3.45) | 1.03 (0.54 to 1.96) | 0.15 |
| Model 2 | 1.0 | 2.09 (0.92 to 4.72) | 1.69 (0.81 to 3.52) | 1.11 (0.57 to 2.16) | 0.10 |
| IFG or IGT | |||||
| %FVC | |||||
| Model 1 | 1.0 | 2.13 (0.93 to 3.03) | 1.85 (1.03 to 3.57) | 2.63 (1.43 to 4.76) | 0.01 |
| Model 2 | 1.0 | 1.48 (0.89 to 2.44) | 1.38 (0.82 to 2.34) | 2.40 (1.30 to 4.44) | 0.04 |
| FEV1/FVC | |||||
| Model 1 | 1.0 | 1.47 (0.84 to 2.56) | 1.47 (0.85 to 2.56) | 1.01 (0.61 to 1.69) | 0.32 |
| Model 2 | 1.0 | 1.47 (0.83 to 2.61) | 1.47 (0.84 to 2.56) | 1.09 (0.64 to 1.84) | 0.21 |
*%FVC quartile; I (highest group) (≥106.0%), II (96.6%≤%FVC<106.0%) III (88.1%≤%FVC<96.6%), IV (lowest group) (%FVC<88.1%).
†FEV1/FVC quartile; I (highest group) (≥85.0%), II (80.9%≤FEV1/FVC<85.0%), III (76.0%≤FEV1/FVC<80.9%), IV (lowest group) (FEV1/FVC<76.0%).
IGT, impaired glucose tolerance; IFG, increased fasting glucose.
Model 1 denotes crude model and model 2, adjusted for age, BMI, pack-year smoking and systolic BP.